Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Hematology

What Blood Tests Are Used to Monitor Gaucher Disease?

At a Glance

Gaucher disease is routinely monitored using two main blood tests: a Complete Blood Count (CBC) to check for low blood cell levels, and the Lyso-Gb1 biomarker test. Lyso-Gb1 is the most accurate way to track your overall disease activity and ensure your specific treatment is working properly.

In this answer

2 sections

01

The Complete Blood Count (CBC)

02

The Lyso-Gb1 Biomarker Test

To monitor how well your body is managing Gaucher disease and whether your treatment is working, your doctor will regularly check your blood. While there are a variety of tests available, two main types of blood tests are the cornerstone of routine monitoring: a Complete Blood Count (CBC) to check your general blood health, and a specific biomarker test called Lyso-Gb1 to track the exact chemical buildup caused by the disease [1][2][3]. Depending on where you are in your treatment journey, you can typically expect these blood draws every 3 to 6 months, or possibly just once a year if your condition is stable [4].

The Complete Blood Count (CBC)

A Complete Blood Count (CBC) is a standard, routine lab test that measures different parts of your blood [1]. Because Gaucher disease involves fatty cells (Gaucher cells) building up in your bone marrow and spleen, it often causes your body to have lower amounts of certain blood cells [5][6].

Your care team will use the CBC to look for three main issues:

  • Low red blood cells (Anemia): Red blood cells carry oxygen throughout your body. When they drop too low, you may feel unusually tired, weak, or short of breath [1][5].
  • Low platelets (Thrombocytopenia): Platelets help your blood clot. A low platelet count can lead to easy bruising or frequent bleeding, such as nosebleeds or bleeding gums [1][7].
  • Low white blood cells (Leukopenia): White blood cells fight off infections. While less prominent than anemia or low platelets, monitoring these helps ensure your immune system is functioning well [1][6].

If you are starting a therapy, such as Enzyme Replacement Therapy (ERT) or Substrate Reduction Therapy (SRT), your doctor will use the CBC to ensure your blood counts are stabilizing or returning to healthy levels over time [8][9].

The Lyso-Gb1 Biomarker Test

While the CBC checks your general blood cell counts, your doctor also needs to know exactly how active the Gaucher disease is inside your body. This is done by measuring a biomarker—a specific substance in your blood that signals how much disease is present [3].

In Gaucher disease, the preferred and most sensitive biomarker is Lyso-Gb1 (also known as glucosylsphingosine) [2][3].

Why is Lyso-Gb1 so important?

Because your body is missing the enzyme needed to break down a specific fat (lipid), that fat accumulates. Lyso-Gb1 is a toxic byproduct of this specific fat buildup [10][3]. By measuring the amount of Lyso-Gb1 in your blood, your doctors get a highly accurate picture of your overall “disease burden” [11][12].

Here is why Lyso-Gb1 is considered the best tool for tracking your progress:

  • It is highly sensitive: Lyso-Gb1 is superior to older traditional markers, such as chitotriosidase or CCL18, because it reacts more predictably to the disease’s actual activity [13][14].
  • It works for everyone: Some patients have a genetic quirk that makes their bodies produce little or no chitotriosidase, making that older test completely useless for them [13]. Lyso-Gb1, on the other hand, is elevated in everyone with active Gaucher disease, making it a reliable test for all patients [2][3].
  • It tracks treatment success: When you start treatment, a successful response will be reflected by a steady drop in your Lyso-Gb1 levels [15][12]. Note that your levels may never reach “zero” or the level of someone without Gaucher disease—the goal is a significant reduction and stabilization [11][12]. Tracking this chemical over time gives your doctor an early, clear warning if your treatment needs to be adjusted—often long before you would ever feel any new symptoms [16][17].

Taking Charge of Your Care

Usually, these blood tests do not require fasting, but it is always best to double-check with your doctor’s office before your appointment [4]. Remember that blood work is just one piece of the puzzle—your care team will likely also order periodic imaging tests, like MRIs, to check the health of your liver, spleen, and bones [18][19].

Ask your doctor for copies of your lab results so you can track your own Lyso-Gb1 and blood count trends over time. Being actively involved in monitoring these numbers can help you feel more confident and in control of your treatment journey [20].

Common questions in this guide

Are Bisphosphonates Safe for Gaucher Disease Bone Loss?Do ERT or SRT Treat Gaucher Neurological Symptoms?Does Gaucher Disease Cause Growth Delays?Can Treatment Reverse Bone Damage in Gaucher Disease?How Is a Gaucher Disease Bone Crisis Treated in the ER?Will My Child Inherit Gaucher Disease?Do You Need a Bone Marrow Biopsy for Gaucher Disease?Is Gaucher Disease Treatment Safe During Pregnancy?Is There a Cure or Gene Therapy for Gaucher Disease?Should Children With Gaucher Disease Avoid Contact Sports?Should Ashkenazi Jews Get Gaucher Carrier Screening?Gaucher Disease: Do I Need Multiple Myeloma Screening?What Is Oculomotor Apraxia in Type 3 Gaucher Disease?What Is the Parkinson's Risk With Gaucher Disease?Why is a CYP2D6 Test Needed for Gaucher Disease SRT?
Why do I need a CBC test for Gaucher disease?
A Complete Blood Count (CBC) checks your general blood health. Because Gaucher cells can build up in the bone marrow and spleen, doctors use the CBC to detect signs of anemia, low platelets, or low white blood cells.
What is the Lyso-Gb1 test?
Lyso-Gb1 is a highly sensitive biomarker found in the blood that indicates how active Gaucher disease is in your body. It helps your care team track your total disease burden and measure how well your treatment is working.
Is Lyso-Gb1 better than the chitotriosidase test?
Yes, Lyso-Gb1 is considered superior because it reacts more predictably to disease activity. Unlike the older chitotriosidase test, which doesn't work for some patients due to genetic differences, Lyso-Gb1 is reliable for everyone with active Gaucher disease.
How often will I need blood tests to monitor my Gaucher disease?
Depending on your specific treatment plan and whether your condition is stable, you can typically expect to have routine blood draws every 3 to 6 months. Some patients with very stable disease may only need tests once a year.
Do I need to fast before my Gaucher disease blood tests?
Generally, routine blood tests for Gaucher disease do not require fasting. However, it is always a good idea to check with your doctor's office before your appointment to ensure no special preparation is needed.

Questions for Your Doctor

5 questions

  • •How frequently will we need to check my CBC and Lyso-Gb1 levels based on my current treatment plan?
  • •What target Lyso-Gb1 level are we aiming for to know if my current therapy is working optimally?
  • •Will you be measuring my Lyso-Gb1 directly, or do you still use older tests like chitotriosidase?
  • •Do my recent CBC results show any signs of bone marrow or spleen involvement that require further imaging?
  • •Do I need to fast or prepare in any specific way before my routine blood draws?

Questions for You

3 questions

  • •What were my baseline platelet and hemoglobin levels at the time of my diagnosis, and how do they compare to my most recent tests?
  • •Have I had a baseline Lyso-Gb1 test done before starting or changing my current treatment?
  • •Am I noticing any practical signs of anemia (like unusual fatigue) or low platelets (like easy bruising) that I should report before my next blood draw?

References

References (20)
  1. 1

    Diet, β-glucocerebrosidase deficiency, and Parkinson's disease.

    Shayman JA

    Journal of lipid research 2024; (65(12)):100689 doi:10.1016/j.jlr.2024.100689.

    PMID: 39490443
  2. 2

    Glucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease.

    Carubbi F, Linari S, Spada M

    International journal of molecular sciences 2026; (27(4)) doi:10.3390/ijms27041705.

    PMID: 41751844
  3. 3

    Comprehensive and long-term outcomes of enzyme replacement therapy followed by stem cell transplantation in children with Gaucher disease type 1 and 3.

    Anurathapan U, Tim-Aroon T, Zhang W, et al.

    Pediatric blood & cancer 2023; (70(3)):e30149 doi:10.1002/pbc.30149.

    PMID: 36562549
  4. 4

    Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.

    Hurvitz N, Dinur T, Becker-Cohen M, et al.

    International journal of molecular sciences 2019; (20(12)) doi:10.3390/ijms20123033.

    PMID: 31234327
  5. 5

    A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact.

    Zimran A, Ruchlemer R, Revel-Vilk S

    Hematology. American Society of Hematology. Education Program 2020; (2020(1)):389-394 doi:10.1182/hematology.2020000123.

    PMID: 33275748
  6. 6

    Non-neuronopathic Gaucher disease (Type I) in an elderly female: a case report.

    Bohara S, Bhattarai S, Khadka M, et al.

    Annals of medicine and surgery (2012) 2024; (86(11)):6780-6783 doi:10.1097/MS9.0000000000002566.

    PMID: 39525705
  7. 7

    Gaucher Disease: Clinical, Biological and Therapeutic Aspects.

    Dandana A, Ben Khelifa S, Chahed H, et al.

    Pathobiology : journal of immunopathology, molecular and cellular biology 2016; (83(1)):13-23 doi:10.1159/000440865.

    PMID: 26588331
  8. 8

    An Overview of Gaucher Disease.

    Méndez-Cobián DA, Guzmán-Silahua S, García-Hernández D, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(24)) doi:10.3390/diagnostics14242840.

    PMID: 39767201
  9. 9

    Gaucher disease - therapeutic aspects in Romania.

    Chis BA, Chis AF, Dumitrascu DL

    Medicine and pharmacy reports 2021; (94(Suppl No 1)):S51-S53 doi:10.15386/mpr-2230.

    PMID: 34527911
  10. 10

    Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.

    Elstein D, Mellgard B, Dinh Q, et al.

    Molecular genetics and metabolism 2017; (122(1-2)):113-120 doi:10.1016/j.ymgme.2017.08.005.

    PMID: 28851512
  11. 11

    Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review.

    Giuffrida G, Markovic U, Condorelli A, et al.

    Orphanet journal of rare diseases 2023; (18(1)):27 doi:10.1186/s13023-023-02623-7.

    PMID: 36782327
  12. 12

    Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.

    Mistry PK, Lukina E, Ben Turkia H, et al.

    American journal of hematology 2021; (96(9)):1156-1165 doi:10.1002/ajh.26276.

    PMID: 34161616
  13. 13

    Glucosylsphingosine (Lyso-Gb1): An Informative Biomarker in the Clinical Monitoring of Patients with Gaucher Disease.

    Gayed MM, Jung SH, Huggins E, et al.

    International journal of molecular sciences 2022; (23(23)) doi:10.3390/ijms232314938.

    PMID: 36499264
  14. 14

    Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease.

    Murugesan V, Liu J, Yang R, et al.

    Blood cells, molecules & diseases 2018; (68()):47-53 doi:10.1016/j.bcmd.2016.12.002.

    PMID: 28003098
  15. 15

    An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan.

    Ida H, Watanabe Y, Sagara R, et al.

    Orphanet journal of rare diseases 2022; (17(1)):401 doi:10.1186/s13023-022-02549-6.

    PMID: 36329499
  16. 16

    Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.

    Dinur T, Bauer P, Beetz C, et al.

    International journal of molecular sciences 2023; (24(4)) doi:10.3390/ijms24043945.

    PMID: 36835356
  17. 17

    Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.

    Cozma C, Cullufi P, Kramp G, et al.

    International journal of molecular sciences 2020; (21(13)) doi:10.3390/ijms21134577.

    PMID: 32605119
  18. 18

    Magnetic resonance imaging and BMB score in the evaluation of bone involvement in Gaucher's disease patients.

    de Mello RA, Mello MB, Pessanha LB

    Radiologia brasileira 2015; (48(4)):216-9 doi:10.1590/0100-3984.2014.0068.

    PMID: 26379319
  19. 19

    Multi-parametric MR imaging using apparent diffusion coefficient and fat fraction in quantification of bone marrow in pediatrics with Gaucher disease.

    Razek AAKA, Abdalla A, Barakat T, et al.

    Clinical imaging 2018; (51()):318-322 doi:10.1016/j.clinimag.2018.06.011.

    PMID: 29958157
  20. 20

    Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey.

    Zimran A, Revel-Vilk S, Dinur T, et al.

    Orphanet journal of rare diseases 2025; (20(1)):43 doi:10.1186/s13023-024-03444-y.

    PMID: 39881421

This page provides educational information about blood tests used to monitor Gaucher disease. It does not replace professional medical advice. Always consult your healthcare provider or hematologist for guidance on interpreting your specific lab results.

Get notified when new evidence is published on Gaucher Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.